Supplementary Figures S1-S5 from Low Expression of the E3 Ubiquitin Ligase CBL Confers Chemoresistance in Human Pancreatic Cancer and Is Targeted by Epidermal Growth Factor Receptor Inhibition

Supplementary Figures S1-S5. Figure S1. MTT assays of CBL knockdown versus isogenic parental PDAC cell lines in serum-supplemented media. Figure S2. Immunoblots of L3.6plCBL siRNA cells versus control highlights autoactivation of EGFR and downstream pAKT when treated with chemotherapy. Figure S3. Chemiluminescent images of a phospho-receptor tyrosine kinase array performed in chemotherapy-treated L3.6plCBL siRNA cells versus control. Figure S4. qRT-PCR, immunoblots and photographs of L3.6plCBL shRNA and Panc-1CBL shRNA tumors versus controls verifies stable gene knockdown and gross similarities between tumors prior to the start of chemotherapy. Figure S5. Photographs of L3.6pl subcutaneous xenografts in NOD-scid-IL2Rγnull mice at the time of necropsy reveals qualitatively that chemoresistance to gemcitabine induced by CBL knockdown is abrogated by the addition of erlotinib.